ALTO NEUROSCIENCE INC (ANRO) Stock Fundamental Analysis

NYSE:ANRO • US02157Q1094

17.62 USD
-1.88 (-9.64%)
At close: Feb 20, 2026
17.49 USD
-0.13 (-0.74%)
After Hours: 2/20/2026, 8:16:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

ANRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While ANRO seems to be doing ok healthwise, there are quite some concerns on its profitability. ANRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ANRO has reported negative net income.
  • In the past year ANRO has reported a negative cash flow from operations.
ANRO Yearly Net Income VS EBIT VS OCF VS FCFANRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -42.35%, ANRO is in line with its industry, outperforming 41.67% of the companies in the same industry.
  • The Return On Equity of ANRO (-55.81%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.35%
ROE -55.81%
ROIC N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANRO Yearly ROA, ROE, ROICANRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ANRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANRO Yearly Profit, Operating, Gross MarginsANRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ANRO has been increased compared to 1 year ago.
  • ANRO has a better debt/assets ratio than last year.
ANRO Yearly Shares OutstandingANRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANRO Yearly Total Debt VS Total AssetsANRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ANRO has an Altman-Z score of 7.08. This indicates that ANRO is financially healthy and has little risk of bankruptcy at the moment.
  • ANRO has a better Altman-Z score (7.08) than 81.25% of its industry peers.
  • A Debt/Equity ratio of 0.20 indicates that ANRO is not too dependend on debt financing.
  • The Debt to Equity ratio of ANRO (0.20) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 7.08
ROIC/WACCN/A
WACCN/A
ANRO Yearly LT Debt VS Equity VS FCFANRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ANRO has a Current Ratio of 15.42. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 15.42, ANRO belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
  • ANRO has a Quick Ratio of 15.42. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ANRO (15.42) is better than 86.98% of its industry peers.
Industry RankSector Rank
Current Ratio 15.42
Quick Ratio 15.42
ANRO Yearly Current Assets VS Current LiabilitesANRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ANRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.51%, which is quite impressive.
EPS 1Y (TTM)76.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ANRO will show a small growth in Earnings Per Share. The EPS will grow by 3.27% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.01%
EPS Next 2Y3.68%
EPS Next 3Y-2.5%
EPS Next 5Y3.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANRO Yearly Revenue VS EstimatesANRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
ANRO Yearly EPS VS EstimatesANRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ANRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANRO Price Earnings VS Forward Price EarningsANRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANRO Per share dataANRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • ANRO's earnings are expected to decrease with -2.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.68%
EPS Next 3Y-2.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ANRO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALTO NEUROSCIENCE INC

NYSE:ANRO (2/20/2026, 8:16:59 PM)

After market: 17.49 -0.13 (-0.74%)

17.62

-1.88 (-9.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-20
Inst Owners58.53%
Inst Owner Change48.88%
Ins Owners6.52%
Ins Owner Change0%
Market Cap547.45M
Revenue(TTM)N/A
Net Income(TTM)-62.26M
Analysts86.25
Price Target31.75 (80.19%)
Short Float %7.96%
Short Ratio7.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.85%
Min EPS beat(2)-3.96%
Max EPS beat(2)23.65%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-3.96%
Max EPS beat(4)23.65%
EPS beat(8)5
Avg EPS beat(8)-44.16%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.07%
EPS NY rev (1m)0%
EPS NY rev (3m)9.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.91
P/tB 4.91
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0
BVpS3.59
TBVpS3.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.35%
ROE -55.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.42
Quick Ratio 15.42
Altman-Z 7.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)251.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y10.01%
EPS Next 2Y3.68%
EPS Next 3Y-2.5%
EPS Next 5Y3.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.54%
EBIT Next 3Y-27.82%
EBIT Next 5Y-14.66%
FCF growth 1Y-91.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.64%
OCF growth 3YN/A
OCF growth 5YN/A

ALTO NEUROSCIENCE INC / ANRO FAQ

What is the ChartMill fundamental rating of ALTO NEUROSCIENCE INC (ANRO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANRO.


What is the valuation status of ALTO NEUROSCIENCE INC (ANRO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALTO NEUROSCIENCE INC (ANRO). This can be considered as Overvalued.


How profitable is ALTO NEUROSCIENCE INC (ANRO) stock?

ALTO NEUROSCIENCE INC (ANRO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ANRO stock?

The Earnings per Share (EPS) of ALTO NEUROSCIENCE INC (ANRO) is expected to grow by 10.01% in the next year.